Mediterranean Journal of Hematology and Infectious Diseases Bcr Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
暂无分享,去创建一个
[1] S. Malek,et al. Chronic Lymphocytic Leukemia , 2019, Methods in Molecular Biology.
[2] D. Porter,et al. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. , 2016, Blood.
[3] M. Hallek,et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. , 2016, The Lancet. Oncology.
[4] Jeffrey A Jones,et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia , 2016, Leukemia.
[5] Jeffrey A Jones,et al. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.
[6] A. Zelenetz,et al. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. , 2015, Blood.
[7] T. Kipps,et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.
[8] Jeffrey A Jones,et al. Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study , 2015 .
[9] A. Wiestner,et al. Atrial Fibrillation in CLL/SLL Patients on Ibrutinib , 2015 .
[10] J. Ritz,et al. Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities , 2015 .
[11] G. Salles,et al. Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL , 2015 .
[12] M. J. Fry,et al. Ibrutinib Inhibits Platelet Integrin &agr;IIb&bgr;3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[13] S. Mourah,et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. , 2015, Blood.
[14] Jeffrey A Jones,et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. , 2015, Blood.
[15] Sudha Seshadri,et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study , 2015, The Lancet.
[16] J. Friedberg,et al. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. , 2015, Blood.
[17] Jeffrey A Jones,et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. , 2015, Blood.
[18] Jeffrey A Jones,et al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. , 2015, JAMA oncology.
[19] J. Byrd,et al. Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib. , 2015, Blood.
[20] A. Zelenetz,et al. Management of adverse events associated with idelalisib treatment: expert panel opinion , 2015, Leukemia & lymphoma.
[21] J. Byrd,et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia , 2015, Cancer Chemotherapy and Pharmacology.
[22] Thomas E. Hughes,et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. , 2015, The Lancet. Oncology.
[23] C. Tam,et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. , 2014, Blood.
[24] M. Keating,et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. , 2014, Blood.
[25] J. Byrd,et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Rosenwald,et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. , 2014, The Lancet. Oncology.
[27] M. Keating,et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation , 2014, Leukemia.
[28] J. Byrd,et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.
[29] Yoonjin Cho,et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. , 2014, Blood.
[30] R. Ulrich,et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. , 2014, Blood.
[31] A. Zelenetz,et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.
[32] Lisa L. Smith,et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). , 2014, Blood.
[33] Jeffrey A Jones,et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. , 2014, The Lancet. Oncology.
[34] Xavier Woot de Trixhe,et al. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies , 2014, Cancer Chemotherapy and Pharmacology.
[35] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[36] Alexander I. Son,et al. Human Cataract Mutations in EPHA2 SAM Domain Alter Receptor Stability and Function , 2012, PloS one.
[37] Alexander I. Son,et al. The role of Eph receptors in lens function and disease , 2012, Science China Life Sciences.
[38] C. Geest,et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. , 2012, Blood.
[39] N. Chiorazzi,et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. , 2012, Blood.
[40] M. Keating,et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. , 2011, Blood.
[41] Jeffrey A Jones,et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.
[42] T. Kurosaki. Regulation of BCR signaling. , 2011, Molecular immunology.
[43] R. Ulrich,et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. , 2011, Blood.
[44] Richard Sherry,et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.
[45] S. Stilgenbauer. Chemoimmunotherapy in chronic lymphocytic leukemia. , 2010, Clinical advances in hematology & oncology : H&O.
[46] R. Ulrich,et al. Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies , 2010 .
[47] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.
[48] Douglas H. Thamm,et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.
[49] P. Ganly,et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] G. Fingerle-Rowson,et al. Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia : a randomised , open-label , phase 3 trial , 2010 .
[51] A. Dart,et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. , 2009, The American journal of pathology.
[52] L. Honigberg,et al. Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase , 2007, ChemMedChem.
[53] Yunyu Zhang,et al. Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy , 2007, Proceedings of the National Academy of Sciences.
[54] Junling Liu,et al. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. , 2006, Blood.
[55] L. Pizzarello. Incidence of Age-Related Cataract Over a 10-Year Interval: The Beaver Dam Eye Study , 2003 .
[56] Ronald Klein,et al. Incidence of age-related cataract over a 10-year interval: the Beaver Dam Eye Study. , 2002, Ophthalmology.
[57] K. Okkenhaug,et al. Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice , 2002, Science.
[58] J. Kinet,et al. Interaction between the Btk PH Domain and Phosphatidylinositol-3,4,5-trisphosphate Directly Regulates Btk* , 2001, The Journal of Biological Chemistry.
[59] B. Cheson,et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[60] S. Watson,et al. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen , 1998, Current Biology.
[61] K. Maloum,et al. Chlorambucil in Indolent Chronic Lymphocytic Leukemia , 1998 .
[62] David R. Kaplan,et al. Direct Regulation of the Akt Proto-Oncogene Product by Phosphatidylinositol-3,4-bisphosphate , 1997, Science.
[63] P. Sperryn,et al. Blood. , 1989, British journal of sports medicine.